Merck (MRK) and Esai (ESALF) (ESAIY) announce a mixed outcome in their Phase 3 LEAP-015 trial for Keytruda/ Lenvima regimen ...

Buying a low-cost index fund will get you the average market return. But if you invest in individual stocks, some ...

Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Merck & Co., Inc. in a note issued to ...

We recently compiled a list of the Billionaire Prem Watsa’s Top 15 Long-Term Stock Picks. In this article, we are going to ...

Merck (MRK) and Eisai (ESAIY) announced results from the Phase 3 LEAP-015 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, ...

Merck and Eisai report mixed results from LEAP-015 trial of Keytruda and Lenvima in HER2-negative gastroesophageal cancer treatment.

The iShares Top 200 Growth ETF focuses on large-cap growth stocks but uses high price-to-book ratios, which I believe is a ...

If you're interested in broad exposure to the Small Cap Value segment of the US equity market, look no further than the JPMorgan BetaBuilders U.S. Small Cap Equity ETF (BBSC), a passively managed ...

Co., Inc. (NYSE:MRK) and Eisai Co., Ltd. (TYO:4523) have announced the latest outcomes from their Phase 3 LEAP-015 trial, ...

Stargate CEOs cite project’s promise of enabling cancer vaccines, though Musk joins critics in questioning partners’ ...

Despite the Dow's early losses, major indices were on track to deliver a second consecutive winning week on Friday, with ...

Research analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of MiMedx Group in a note issued to ...